{"id":2785,"date":"2025-02-03T15:39:17","date_gmt":"2025-02-03T12:39:17","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2785"},"modified":"2025-03-07T13:17:20","modified_gmt":"2025-03-07T10:17:20","slug":"entrada-therapeutics-receives-uk-authorization-to-begin-elevate-44-201","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/ar\/entrada-therapeutics-receives-uk-authorization-to-begin-elevate-44-201\/","title":{"rendered":"\u062d\u0635\u0644\u062a \u0634\u0631\u0643\u0629 Entrada Therapeutics \u0639\u0644\u0649 \u062a\u0631\u062e\u064a\u0635 \u0645\u0646 \u0627\u0644\u0645\u0645\u0644\u0643\u0629 \u0627\u0644\u0645\u062a\u062d\u062f\u0629 \u0644\u0628\u062f\u0621 \u0627\u0633\u062a\u062e\u062f\u0627\u0645 ELEVATE-44-201"},"content":{"rendered":"<p class=\"wp-block-paragraph\">\u062a\u0645\u062a \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u0639\u0644\u0649 ELEVATE-44-201\u060c \u0648\u0647\u064a \u062f\u0631\u0627\u0633\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 1\/2 \u0644\u062c\u0631\u0639\u0629 \u0645\u062a\u0635\u0627\u0639\u062f\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 (MAD) \u0644\u0640 ENTR-601-44\u060c \u0645\u0646 \u0642\u0628\u0644 \u0648\u0643\u0627\u0644\u0629 \u062a\u0646\u0638\u064a\u0645 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0648\u0645\u0646\u062a\u062c\u0627\u062a \u0627\u0644\u0631\u0639\u0627\u064a\u0629 \u0627\u0644\u0635\u062d\u064a\u0629 (MHRA) \u0641\u064a \u0627\u0644\u0645\u0645\u0644\u0643\u0629 \u0627\u0644\u0645\u062a\u062d\u062f\u0629 \u0648\u0644\u062c\u0646\u0629 \u0623\u062e\u0644\u0627\u0642\u064a\u0627\u062a \u0627\u0644\u0628\u062d\u062b \u0644\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0645\u0646\u062a\u062c \u0637\u0628\u064a \u062a\u062c\u0631\u064a\u0628\u064a. \u062a\u0647\u062f\u0641 \u0627\u0644\u062f\u0631\u0627\u0633\u0629 \u0625\u0644\u0649 \u0639\u0644\u0627\u062c \u0636\u0645\u0648\u0631 \u0627\u0644\u0639\u0636\u0644\u0627\u062a \u062f\u0648\u0634\u064a\u0646 (DMD) \u0641\u064a \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u0644\u062f\u064a\u0647\u0645 \u0637\u0641\u0631\u0629 \u0645\u0624\u0643\u062f\u0629 \u0641\u064a \u062c\u064a\u0646 DMD \u0642\u0627\u0628\u0644\u0629 \u0644\u062a\u062e\u0637\u064a \u0627\u0644\u0625\u0643\u0633\u0648\u0646 44.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\u0645\u0627 \u0647\u064a \u0627\u0644\u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 ELEVATE-44-201\u061f<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">ELEVATE-44-201 \u0647\u064a \u062f\u0631\u0627\u0633\u0629 \u0639\u0627\u0644\u0645\u064a\u0629 \u0645\u0643\u0648\u0646\u0629 \u0645\u0646 \u062c\u0632\u0623\u064a\u0646\u060c \u0639\u0634\u0648\u0627\u0626\u064a\u0629\u060c \u0645\u0632\u062f\u0648\u062c\u0629 \u0627\u0644\u062a\u0639\u0645\u064a\u0629\u060c \u062e\u0627\u0636\u0639\u0629 \u0644\u0644\u062a\u062d\u0643\u0645 \u0627\u0644\u0648\u0647\u0645\u064a\u060c \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 1\/2 \u0644\u062a\u0642\u064a\u064a\u0645 \u0633\u0644\u0627\u0645\u0629 \u0648\u062a\u062d\u0645\u0644 \u0648\u0641\u0639\u0627\u0644\u064a\u0629 ENTR-601-44 \u0641\u064a \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0645\u062a\u0646\u0642\u0644\u064a\u0646 \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0636\u0645\u0648\u0631 \u0627\u0644\u0639\u0636\u0644\u0627\u062a \u062f\u0648\u0634\u064a\u0646 \u0648\u0627\u0644\u0630\u064a\u0646 \u064a\u0645\u0643\u0646 \u062a\u062e\u0637\u064a \u0627\u0644\u0625\u0643\u0633\u0648\u0646 44.<\/p>","protected":false},"excerpt":{"rendered":"<p>ELEVATE-44-201, a Phase 1\/2 multiple ascending dose (MAD) clinical study of ENTR-601-44, was authorized by the UK&#8217;s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for the Clinical Trial of an Investigational Medicinal Product. The study aims to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2788,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[235,49,233,234,141,127,77,48],"class_list":["post-2785","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevate-44-201","tag-england","tag-entrada","tag-entrada-therapeutics","tag-exon-44","tag-exon-44-skipping","tag-exon-skipping","tag-uk"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/posts\/2785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/comments?post=2785"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/posts\/2785\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/media\/2788"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/media?parent=2785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/categories?post=2785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/tags?post=2785"}],"curies":[{"name":"\u0648\u0648\u0631\u062f\u0628\u0631\u064a\u0633","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}